OPCML: A Promising Biomarker and Therapeutic Avenue

Cui, 2008, OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation, PLoS One, 3, 10.1371/annotation/f394b95b-c731-41a3-b0dc-be25fb6a227c Xing, 2017, Down-regulated expression of OPCML predicts an unfavorable prognosis and promotes disease progression in human gastric cancer, BMC Cancer, 17, 268, 10.1186/s12885-017-3203-y Roy, 1988, A monoclonal antibody that inhibits opioid binding to rat brain membranes, Biochem. Biophys. Res. Commun., 154, 688, 10.1016/0006-291X(88)90194-5 Yamada, 2007, Synaptic adhesion molecule OBCAM; synaptogenesis and dynamic internalization, Brain Res., 1165, 5, 10.1016/j.brainres.2007.04.062 Sugimoto, 2012, Overexpression of IgLON cell adhesion molecules changes proliferation and cell size of cortical astrocytes, Cell Biochem. Funct., 30, 400, 10.1002/cbf.2813 Sellar, 2003, OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer, Nat. Genet., 34, 337, 10.1038/ng1183 McKie, 2012, The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer, Cancer Discov., 2, 156, 10.1158/2159-8290.CD-11-0256 Zanini, 2017, The tumor-suppressor protein OPCML potentiates anti-EGFR- and anti-HER2-targeted therapy in HER2-positive ovarian and breast cancer, Mol. Cancer Ther., 16, 2246, 10.1158/1535-7163.MCT-17-0081 Antony, 2018, The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer, EMBO Rep., 19, 10.15252/embr.201745670 Zhou, 2014, Detection of circulating methylated opioid binding protein/cell adhesion molecule-like gene as a biomarker for ovarian carcinoma, Clin. Lab., 60, 759, 10.7754/Clin.Lab.2013.130446 Duarte-Pereira, 2011, Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma, Eur. J. Cancer, 47, 1106, 10.1016/j.ejca.2010.12.025 Zhou, 2014, Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival, Clin. Chem. Lab. Med., 52, 735, 10.1515/cclm-2013-0736 Castano-Rodriguez, 2018, OPCML is hypermethylated in a subset of patients with metaplastic changes in their esophagus, Biomark. Res., 6, 35, 10.1186/s40364-018-0150-y Li, 2015, OPCML is frequently methylated in human colorectal cancer and its restored expression reverses EMT via downregulation of smad signaling, Am. J. Cancer Res., 5, 1635 Margetts, 2008, Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma, Endocr. Relat. Cancer, 15, 777, 10.1677/ERC-08-0072